Neoadjuvant breast cancer treatment response; tumor size evaluation through different conventional imaging modalities in the NeoDense study

References

• Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94(10):1189–1200.
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G, Smith R, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21(13):2600–2608.
   PubMed Web of Science ®Google Scholar
• Masood S. Neoadjuvant chemotherapy in breast cancers. Womens Health (Lond). 2016;12(5):480–491.
   PubMedGoogle Scholar
• Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;30(10):1541–1557.
   PubMed Web of Science ®Google Scholar
• Cain H, Macpherson IR, Beresford M, et al. Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol (R Coll Radiol). 2017;29(10):642–652.
   PubMed Web of Science ®Google Scholar
• Denduluri N, Chavez-MacGregor M, Telli ML, et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36(23):2433–2443.
   PubMed Web of Science ®Google Scholar
• Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–2159.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617–628.
   PubMed Web of Science ®Google Scholar
• Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830–849.
   PubMed Web of Science ®Google Scholar
• Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol. 2005;184(3):868–877.
   PubMed Web of Science ®Google Scholar
• Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243(2):257–264.
   PubMed Web of Science ®Google Scholar
• Schulz-Wendtland R. Neoadjuvant chemotherapy-monitoring: clinical examination, ultrasound, mammography, MRI, elastography: only one, only few or all? Eur J Radiol. 2012;81(Suppl. 1):S147–S148.
   PubMedGoogle Scholar
• Schaefgen B, Mati M, Sinn HP, et al. Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol. 2016;23(3):789–795.
   PubMed Web of Science ®Google Scholar
• Park J, Chae EY, Cha JH, et al. Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol. 2018;108:261–268.
   PubMed Web of Science ®Google Scholar
• Atkins JJ, Appleton CM, Fisher CS, et al. Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer? J Oncol. 2013;2013:1–7.
   Google Scholar
• Peintinger F, Kuerer HM, Anderson K, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol. 2006;13(11):1443–1449.
   PubMed Web of Science ®Google Scholar
• Fatayer H, Sharma N, Manuel D, et al. Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. Eur J Surg Oncol. 2016;42(7):965–972.
   PubMed Web of Science ®Google Scholar
• Dialani V, Chadashvili T, Slanetz PJ. Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol. 2015;22(5):1416–1424.
   PubMed Web of Science ®Google Scholar
• Hylton NM, Blume JD, Bernreuter WK, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–672.
   PubMed Web of Science ®Google Scholar
• Yu N, Leung VWY, Meterissian S. MRI performance in detecting pCR after neoadjuvant chemotherapy by molecular subtype of breast cancer. World J Surg. 2019;43(9):2254–2261.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya M, Ryan D, Carpenter R, et al. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2008;98(2):289–293.
   PubMed Web of Science ®Google Scholar
• van der Noordaa MEM, van Duijnhoven FH, Loo CE, et al. Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast. 2018;40:76–81.
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(10):1674.
   PubMed Web of Science ®Google Scholar
• Regionalt Cancercentrum. Bröstcancer Nationellt vårdprogram; 2020; [cited 2020 Sep 22]. Available from: https://kunskapsbanken.cancercentrum.se/globalassets/cancerdiagnoser/brost/vardprogram/nationellt-vardprogram-brostcancer.pdf
   Google Scholar
• Di Cosimo S, Campbell C, Azim HA Jr., et al. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: results from Neo-ALTTO. Eur J Cancer. 2018;89:42–48.
   PubMed Web of Science ®Google Scholar
• Saal LH, Vallon-Christersson J, Hakkinen J, et al. The Sweden Cancerome Analysis Network – Breast (SCAN-B) initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.
   PubMed Web of Science ®Google Scholar
• Ryden L, Loman N, Larsson C, et al. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg. 2018;105(2):e158–e168.
   PubMed Web of Science ®Google Scholar
• Skarping I, Fornvik D, Heide JU, et al. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. Breast. 2020;53:33–41.
   PubMed Web of Science ®Google Scholar
• Bossuyt V, Provenzano E, Symmans WF, et al. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015;26(7):1280–1291.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Semiglazov V. RECIST for response (clinical and imaging) in neoadjuvant clinical trials in operable breast cancer. J Natl Cancer Inst Monogr. 2015;2015(51):21–23.
   PubMedGoogle Scholar
• McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276–282.
   PubMed Web of Science ®Google Scholar
• Huober J, von Minckwitz G, Denkert C, et al. Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat. 2010;124(1):133–140.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Gonzalez-Angulo AM, Hunt KK, et al. Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol. 2011;18(4):932–938.
   PubMed Web of Science ®Google Scholar
• Regionalt cancercentrum. Nationellt vårdprogram Bröstcancer; 2019; [cited 2020 Sep 22]. Available from: http://www.swebcg.se/wp-content/uploads/2016/09/nationellt-vardprogram-brostcancer.pdf
   Google Scholar
• Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;18(2):CD005002.
   Google Scholar
• Mohiuddin JJ, Deal AM, Lund JL, et al. Evaluating the effectiveness of neoadjuvant chemotherapy in reducing mastectomy for women with breast cancer. JNCI Cancer Spectr. 2017;1(1):pkx004.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31(29):3623–3630.
   PubMed Web of Science ®Google Scholar
• Sato N, Masuda N, Morimoto T, et al. Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study. Cancer Med. 2018;7(7):3044–3056.
   PubMed Web of Science ®Google Scholar
• Nitz UA, Gluz O, Christgen M, et al. De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR– phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/– weekly paclitaxel. Ann Oncol. 2017;28(11):2768–2772.
   PubMed Web of Science ®Google Scholar
• Thompson AM, Moulder-Thompson SL. Neoadjuvant treatment of breast cancer. Ann Oncol. 2012;23(Suppl. 10):x231–x236.
   PubMed Web of Science ®Google Scholar
• Reyal F, Hamy AS, Piccart MJ. Neoadjuvant treatment: the future of patients with breast cancer. ESMO Open. 2018;3(4):e000371.
   PubMed Web of Science ®Google Scholar
• Partridge SC, Zhang Z, Newitt DC, et al. Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer: the ACRIN 6698 Multicenter Trial. Radiology. 2018;289(3):618–627.
   PubMed Web of Science ®Google Scholar
• Gebhart G, Gamez C, Holmes E, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54(11):1862–1868.
   PubMed Web of Science ®Google Scholar
• Keune JD, Jeffe DB, Schootman M, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg. 2010;199(4):477–484.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative G. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018;19(1):27–39.
   PubMed Web of Science ®Google Scholar
• Volders JH, Negenborn VL, Spronk PE, et al. Breast-conserving surgery following neoadjuvant therapy—a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1–12.
   PubMed Web of Science ®Google Scholar
• O’Halloran N, Lowery A, Curran C, et al. A review of the impact of neoadjuvant chemotherapy on breast surgery practice and outcomes. Clin Breast Cancer. 2019;19(5):377–382.
   PubMed Web of Science ®Google Scholar
• King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12(6):335–343.
   PubMed Web of Science ®Google Scholar
• Fowler AM, Mankoff DA, Joe BN. Imaging neoadjuvant therapy response in breast cancer. Radiology. 2017;285(2):358–375.
   PubMed Web of Science ®Google Scholar
• Pickles MD, Lowry M, Manton DJ, et al. Prognostic value of DCE-MRI in breast cancer patients undergoing neoadjuvant chemotherapy: a comparison with traditional survival indicators. Eur Radiol. 2015;25(4):1097–1106.
   PubMed Web of Science ®Google Scholar
• Li W, Newitt DC, Yun B, et al. Tumor sphericity predicts response in neoadjuvant chemotherapy for invasive breast cancer. Tomography. 2020;6(2):216–222.
   PubMed Web of Science ®Google Scholar
• Humbert O, Cochet A, Coudert B, et al. Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist. 2015;20(2):94–104.
   PubMed Web of Science ®Google Scholar
• Guggenmoos-Holzmann I, van Houwelingen HC. The (in)validity of sensitivity and specificity. Stat Med. 2000;19(13):1783–1792.
   PubMed Web of Science ®Google Scholar
• Slanetz PJ, Moy L, Baron P, et al. ACR appropriateness criteria® monitoring response to neoadjuvant systemic therapy for breast cancer. J Am Coll Radiol. 2017;14(11S):S462–S475.
   PubMedGoogle Scholar
• Mghanga FP, Lan X, Bakari KH, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer. 2013;13(4):271–279.
   PubMed Web of Science ®Google Scholar
• McDermott GM, Welch A, Staff RT, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102(1):75–84.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang C, Liu J, et al. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat. 2012;131(2):357–369.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Im YH, Han BK, et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI. Acta Oncol. 2007;46(7):996–1003.
   PubMed Web of Science ®Google Scholar
• Marinovich ML, Sardanelli F, Ciatto S, et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669–677.
   PubMed Web of Science ®Google Scholar
• Chen L, Yang Q, Bao J, et al. Direct comparison of PET/CT and MRI to predict the pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. Sci Rep. 2017;7(1):8479.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Kim HH, Ahn JH, et al. Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol. 2011;84(1003):612–620.
   PubMed Web of Science ®Google Scholar
• Hashimoto BE, Morgan GN, Kramer DJ, et al. Systematic approach to difficult problems in breast sonography. Ultrasound Q. 2008;24(1):31–38.
   PubMedGoogle Scholar
• Hooley RJ, Scoutt LM, Philpotts LE. Breast ultrasonography: state of the art. Radiology. 2013;268(3):642–659.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422.
   PubMed Web of Science ®Google Scholar